G. Blijham , G. Spitzer , J. Litam , A.R. Zander , D.S. Verma , L. Vellekoop , M.L. Samuels , K.B. McCredie , K.A. Dicke
{"title":"The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support","authors":"G. Blijham , G. Spitzer , J. Litam , A.R. Zander , D.S. Verma , L. Vellekoop , M.L. Samuels , K.B. McCredie , K.A. Dicke","doi":"10.1016/0014-2964(81)90252-8","DOIUrl":null,"url":null,"abstract":"<div><p>Thirteen patients with disseminated nonseminomatous germ cell carcinoma, failing to respond to extensive prior chemotherapy including <em>cis</em>-platinum, were treated with high dose chemotherapy. Cyclophosphamide <em>(4.5g/m<sup>2</sup>)</em> and epipodophyllotoxin <em>(VP-16) (600 mg/m<sup>2</sup>)</em> were given followed by autologous bone marrow transplantation. In some cases <em>1,3</em> bis (β-chloroethyl)-<em>1</em>-nitrosourea (BCNU), adriamycin or platinum were also administered. Of <em>10</em> patients evaluable for response <em>9</em> responded; <em>4</em> patients achieved a complete remission and <em>3</em> a partial remission. Median response duration was <em>15</em> weeks (range <em>4</em> to <em>20+ weeks</em>). Four patients died from treatment-related infections; <em>2</em> of whom entered the program already with fever and <em>3</em> of whom died after hematopoietic recovery. Major toxicities were bacterial and fungal infections. In patients treated with cyclophosphamide and VP-<em>16</em> only, no fever was seen in <em>3</em> out of <em>9</em> courses. Granulocyte transfusion was given in only <em>1</em> of <em>9</em> courses. Neutrophils recovered to greater than <em>1.5 × 10<sup>9</sup>/liter</em> by day <em>18–35</em> (median <em>23</em>) and platelets greater than <em>100 × 10<sup>9</sup>/liter</em> by day <em>16</em> to <em>42+</em> (median <em>21</em>). Further experience with high dose cyclophosphamide and VP-<em>16</em> followed by autologous bone marrow transplantation is needed to evaluate its value in the management of patients with disseminated nonseminomatous germ cell tumor failing front line conventional chemotherapy.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 433-441"},"PeriodicalIF":0.0000,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90252-8","citationCount":"53","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer (1965)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0014296481902528","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 53
Abstract
Thirteen patients with disseminated nonseminomatous germ cell carcinoma, failing to respond to extensive prior chemotherapy including cis-platinum, were treated with high dose chemotherapy. Cyclophosphamide (4.5g/m2) and epipodophyllotoxin (VP-16) (600 mg/m2) were given followed by autologous bone marrow transplantation. In some cases 1,3 bis (β-chloroethyl)-1-nitrosourea (BCNU), adriamycin or platinum were also administered. Of 10 patients evaluable for response 9 responded; 4 patients achieved a complete remission and 3 a partial remission. Median response duration was 15 weeks (range 4 to 20+ weeks). Four patients died from treatment-related infections; 2 of whom entered the program already with fever and 3 of whom died after hematopoietic recovery. Major toxicities were bacterial and fungal infections. In patients treated with cyclophosphamide and VP-16 only, no fever was seen in 3 out of 9 courses. Granulocyte transfusion was given in only 1 of 9 courses. Neutrophils recovered to greater than 1.5 × 109/liter by day 18–35 (median 23) and platelets greater than 100 × 109/liter by day 16 to 42+ (median 21). Further experience with high dose cyclophosphamide and VP-16 followed by autologous bone marrow transplantation is needed to evaluate its value in the management of patients with disseminated nonseminomatous germ cell tumor failing front line conventional chemotherapy.